FrancophonIA/ELRC3.0 huggingface dataset:
English: One ml contains 1.11 mg hydrocortisone aceponate, 15.1 mg miconazole (as nitrate) and 1,505 IU gentamicin (as sulphate).
Danish: En ml indeholder 1,11 mg hydrocortisonaceponat, 15,1 mg miconazol (som nitrat) og 1505 IU gentamicin (som sulfat).
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Easotic ear drops, suspension for dogs
Danish: VETERINÆRLÆGEMIDLETS NAVN Easotic øredråber suspension, til hunde
English: A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer responsible for batch release VIRBAC
Danish: A. FREMSTILLER ANSVARLIG FOR BATCHFRIGIVELSE Navn og adresse på fremstilleren af det biologisk aktive stof VIRBAC
English: In case of eye irritation, seek medical advice.
Danish: Søg lægehjælp i tilfælde af øjenirritationer.
English: METHOD AND ROUTE(S) OF ADMINISTRATION For auricular use only.
Danish: ANVENDELSESMÅDE OG INDGIVELSESVEJ(E) Kun til brug i ørerne.
English: Introduce the atraumatic canula in the ear canal.
Danish: Indfør den atraumatiske kanyle i øregangen.
English: PACKAGE LEAFLET : Easotic ear drops, suspension for dogs
Danish: INDLÆGSSEDDEL: Easotic øredråber suspension, til hunde
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS MULTI-DOSE CONTAINER
Danish: MINDSTEKRAV TIL OPLYSNINGER PÅ SMÅ INDRE PAKNINGER ETIKET TIL MULTIDOSISBEHOLDER
English: France VIRBAC 13ème rue - L.I.D - BP 27 06517 Carros Hrvatska VIRBAC
Danish: France VIRBAC 13ème rue - L.I.D - BP 27 F-06517 Carros
English: 1 dose x 5
Danish: 1 dosis x 5
English: SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE
Danish: EVENTUELLE SÆRLIGE FORHOLDSREGLER VED BORTSKAFFELSE AF UBRUGTE LÆGEMIDLER ELLER AFFALD FRA SÅDANNE
English: 1 dose x 50
Danish: 1 dosis x 50
English: • Introduce the atraumatic cannula in the ear canal.
Danish: • Indfør den atraumatiske kanyle i øregangen.
English: 1 dose x 10
Danish: 1 dosis x 10
English: ROUTE(S) OF ADMINISTRATION (Reference is made to the drawing in section 1)
Danish: INDGIVELSESVEJ(E) (Se tegning under pkt.
English: (Reference is made to the drawing in section 1)
Danish: (Se tegning under pkt.
English: Single-dose container:
Danish: Enkeltdosisbeholder:
English: Tel: 32 (0) 16 38 72 60
Danish: B-3001 Leuven Tel: 32 (0) 16 38 72 60
English: Cardboard box containing 5, 10, 50, 100 or 200 pipettes.
Danish: Pipette bestående af high density polyethylen (krop og kanyle) med en stålkugle i. Æske med 5, 10, 50, 100 eller 200 pipetter
English: NAME OF THE VETERINARY MEDICINAL PRODUCT
Danish: VETERINÆRLÆGEMIDLETS NAVN Easotic
English: Miconazole as nitrate
Danish: Miconazolnitrat
English: Tel.: 0033/4.92.08.73.00 Fax: 0033/4.92.08.73.48 E-mail: dar@virbac.fr
Danish: 0033/4.92.08.73.48 E-mail.
English: Auricular use.
Danish: Kun til brug i ørerne.
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PIPETTE NAME OF THE VETERINARY MEDICINAL PRODUCT Easotic
Danish: MINDSTEKRAV TIL OPLYSNINGER PÅ SMÅ INDRE PAKNINGER PIPETTE
English: Tel: + 372 6 709 006 E-mail: zoovet@zoovet.ee
Danish: E-mail: zoovet@zoovet.ee
English: Easotic ear drops, suspension for dogs
Danish: Øredråber, suspension
English: CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 10 ml (10 doses).
Danish: LÆGEMIDDELFORM Øredråber, suspension PAKNINGSSTØRRELSE 10 ml (10 doser).
English: Slovenija VIRBAC 1ère avenue 2065 m - L.I.D 06516 Carros FRANCE
Danish: Hrvatska VIRBAC 1ère avenue 2065 m - L.I.D 06516 Carros FRANCE
English: QUANTITY OF THE ACTIVE SUBSTANCE(S) Hydrocortisone aceponate 1.11 mg/ml, Miconazole as nitrate 15.1 mg/ml, Gentamicin as sulphate 1,505 IU/ml.
Danish: MÆNGDEN AF AKTIVT STOF (AKTIVE STOFFER) Hydrocortisonaceponat 1,11 mg/ ml Miconazolnitrat
English: Hydrocortisone aceponate - Miconazole - Gentamicin
Danish: Hydrocortisonaceponat 1,11 mg/ml Miconazolnitrat
English: STATEMENT OF ACTIVE SUBSTANCES Hydrocortisone aceponate 1.11 mg/ml, Miconazole as nitrate 15.1 mg/ml, Gentamicin as sulphate 1,505 IU/ml.
Danish: ANGIVELSE AF AKTIVE STOFFER Hydrocortisonaceponat 1,11 mg/ ml Miconazolnitrat
English: Suomi/Finland VIRBAC 1ère avenue 2065 m - L.I.D 06516 Carros FRANCE
Danish: Suomi/Finland VIRBAC 1ère avenue 2065 m - L.I.D F-06516 Carros Tel: 33 (0) 4 92 08 73 00
English: 2 pre-filled pens + 2 alcohol wipes
Danish: 2 fyldte penne + 2 alkoholservietter
English: 2 dose-dispenser cartridges + 2 alcohol wipes
Danish: 2 dosisleverende cylinderampuller + 2 alkoholservietter
English: Pre-filled syringe (glass) with needle guard
Danish: Fyldt injektionssprøjte (glas) med kanylekappe
English: London, 24 January 2008 Doc.
Danish: London, den 24. januar 2008 Ref.-dok.
English: The company that applied for authorisation is Wyeth Europa Ltd.
Danish: Virksomheden, som ansøgte om tilladelse, er Wyeth Europa Ltd.
English: Ref. EMEA/37537/2008
Danish: EMEA/186668/2008
English: A small proportion of the patients whose disease had come back after one previous course of treatment achieved complete remission.
Danish: En lille andel af de patienter, hvis sygdom var vendt tilbage efter ét tidligere behandlingsforløb, opnåede fuldstændig bedring.
English: International non-proprietary name (INN): gemtuzumab ozogamicin
Danish: Internationalt fællesnavn (INN): gemtuzumab ozogamicin
English: If you are in a clinical trial or compassionate use programme and need more information about your treatment, contact the doctor who is giving it to you.
Danish: Hvis du deltager i en klinisk undersøgelse eller i et program for anvendelse med særlig udleveringstilladelse og har brug for yderligere oplysninger om din behandling, bedes du kontakte den læge, der giver dig behandlingen.
English: QUESTIONS AND ANSWERS ON RECOMMENDATION FOR THE REFUSAL OF THE MARKETING AUTHORISATION for MYLOTARG
Danish: SPØRGSMÅL OG SVAR VEDRØRENDE ANBEFALINGEN AF AFSLAG PÅ ANSØGNINGEN OM MARKEDSFØRINGSTILLADELSE for MYLOTARG
English: After having considered the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the refusal of the marketing authorisation on 24 January 2008.
Danish: Efter at have drøftet begrundelserne for denne anmodning revurderede CHMP den oprindelige udtalelse og bekræftede anbefalingen af afslag på ansøgningen om markedsføringstilladelse den 24. januar 2008.
English: These included severe and long-lasting bone marrow suppression causing low levels of white blood cells and platelets, liver problems, and side effects related to the infusion, such as chills, fever and low blood pressure.
Danish: Bivirkningerne omfattede svær og langvarig knoglemarvssuppression med deraf følgende lavt antal hvide blodceller og blodplader, leverproblemer og bivirkninger i forbindelse med infusionen såsom kuldegysninger, feber og lavt blodtryk.
English: What is Mylotarg?
Danish: Hvad er Mylotarg?
English: The effects of Mylotarg were first tested in experimental models before being studied in humans.
Danish: Virkningerne af Mylotarg blev først afprøvet i forsøgsmodeller, inden de blev undersøgt hos mennesker.
English: However, it was difficult to compare the effectiveness of Mylotarg and other treatments used for this disease, in terms of how long remission would last, how long it would take until the disease got worse, or what the medicines' effects would be on survival.
Danish: Det var dog vanskeligt at sammenligne virkningen af Mylotarg med andre behandlingsformer, der anvendes ved denne sygdom, med hensyn til, hvor længe bedringen ville vare, hvor lang tid der ville gå, før sygdommen forværredes, eller hvilken virkning lægemidlet ville have på overlevelsen.
English: Mylotarg was not compared to any other treatment in any of the studies.
Danish: Mylotarg blev ikke sammenlignet med andre behandlinger i nogen af undersøgelserne.
English: The calicheamicin then breaks up the leukaemia cells' DNA, eventually killing the cells.
Danish: Calicheamicinen ødelægger derefter leukæmicellernes dna og dræber således cellerne.
English: In all three studies, the main measure of effectiveness was the proportion of patients who achieved ‘complete remission' after a seven-month course of treatment.
Danish: I alle tre undersøgelser var det primære mål for virkningen andelen af patienter, som var i fuldstændig bedring efter syv måneders behandling.
English: What was Mylotarg expected to be used for?
Danish: Hvad forventedes Mylotarg anvendt til?
English: It contains the active substance gemtuzumab ozogamicin.
Danish: Det indeholder det aktive stof gemtuzumab ozogamicin.
English: The company also stated that it will continue to supply Mylotarg for use in existing, ongoing clinical trials.
Danish: Virksomheden oplyste også, at den fortsat vil udlevere Mylotarg til igangværende, løbende kliniske undersøgelser.
English: The effects of Mylotarg were studied in three main studies involving a total of 277 patients with CD33-positive acute myeloid leukaemia, whose disease had come back after one previous course of treatment.
Danish: Virkningerne af Mylotarg blev undersøgt i tre hovedundersøgelser, hvori der i alt deltog 277 patienter med CD33-positiv akut myeloid leukæmi, hvis sygdom var vendt tilbage efter ét tidligere behandlingsforløb.
English: On 20 September 2007, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Mylotarg 5 mg powder for solution for infusion, intended for the treatment of acute myeloid leukaemia.
Danish: Den 20. september 2007 vedtog Udvalget for Humanmedicinske Lægemidler (CHMP) en negativ udtalelse, hvori udvalget anbefaler afslag på ansøgningen om markedsføringstilladelse for lægemidlet Mylotarg 5 mg pulver til opløsning til infusion til behandling af akut myeloid leukæmi.
English: Mylotarg was to be used to treat patients whose disease had come back after one previous course of treatment, and who were not suitable for other types of intensive chemotherapy such as highdose cytarabine (another anticancer medicine).
Danish: Mylotarg skulle anvendes til behandling af patienter, hvis sygdom var vendt tilbage efter ét tidligere behandlingsforløb, og som ikke var egnede til andre typer intensiv kemoterapi såsom højdosis-cytarabin, der er et andet lægemiddel mod kræft.
English: The company informed the CHMP that patients currently included in compassionate use programmes will continue to receive Mylotarg until they have finished their course of treatment.
Danish: Virksomheden har informeret CHMP om, at patienter, der for øjeblikket deltager i programmer for anvendelse af Mylotarg med særlig udleveringstilladelse, fortsat vil få Mylotarg, indtil de har afsluttet deres behandlingsforløb.
English: Inside the cells, the cytotoxic substance, which is called calicheamicin, is released.
Danish: Inden i cellerne frigives det cytotoksiske stof, der kaldes calicheamicin.
English: Mylotarg was designated as an orphan medicinal product on 18 October 2000 for acute myeloid leukaemia.
Danish: Mylotarg blev udpeget som lægemiddel til sjældne sygdomme den 18. oktober 2000 for akut myeloid leukæmi.
English: It was to be used in patients who were ‘CD33-positive', meaning that their cancerous white blood cells had a protein called CD33 on their surface.
Danish: Det skulle gives til patienter, som var såkaldt CD33-positive, hvilket betyder, at der er et protein kaldet CD33 på overfladen af de kræftramte hvide blodceller.
English: Mylotarg was expected to be used to treat acute myeloid leukaemia, a type of cancer of the white blood cells.
Danish: Mylotarg forventedes anvendt til behandling af akut myeloid leukæmi, der er en type kræft i de hvide blodceller.
English: How is Mylotarg expected to work?
Danish: Hvordan forventes Mylotarg at virke?
English: What are the consequences of the refusal for patients in clinical trials or compassionate use programmes using Mylotarg?
Danish: Hvilke konsekvenser har afslaget for patienter, der deltager i kliniske undersøgelser med Mylotarg eller i programmer for anvendelse af Mylotarg med særlig udleveringstilladelse?
English: At that point in time, the CHMP was of the opinion that there was insufficient evidence to establish the effectiveness of Mylotarg in the treatment of acute myeloid leukaemia, and therefore that the medicine's benefits did not outweigh its risks.
Danish: På daværende tidspunkt var CHMP af den opfattelse, at der ikke forelå tilstrækkelig dokumentation til at kunne bedømme Mylotargs virkning ved behandling af akut myeloid leukæmi, og at fordelene ved Mylotarg derfor ikke opvejede risiciene.
English: When the antibody attaches to CD33, the cells absorb the antibody, as well as the cytotoxic substance that it is attached to.
Danish: Når antistoffet binder sig til CD33, absorberer cellen både antistoffet og det cytotoksiske stof, som antistoffet er bundet til.
English: The CHMP was concerned that the studies of Mylotarg had not shown a benefit of the medicine, because of the way they were designed.
Danish: CHMP var betænkelig ved, at undersøgelserne af Mylotarg ikke viste nogen gavnlig virkning ved lægemidlet på grund af undersøgelsens udformning.
English: Mylotarg is a powder that is made up into a solution for infusion (drip into a vein).
Danish: Mylotarg er et pulver, der anvendes til at lave en opløsning til infusion (drop i en vene).
English: The Committee noted that there were side effects associated with Mylotarg.
Danish: Udvalget noterede sig bivirkningerne ved Mylotarg.
English: The monoclonal antibody part of the active substance (gemtuzumab) has been designed to bind to CD33, an antigen which is found on the surface of acute myeloid leukaemia cells in about 80% of patients.
Danish: Det monoklonale antistof, der er en del af det aktive stof (gemtuzumab), er i stand til at binde sig til CD33, der er et antigen, som findes på overfladen af akut myeloid leukæmi-cellerne hos ca. 80 % af patienterne.
English: The active substance in Mylotarg, gemtuzumab ozogamicin, is a cytotoxic (cell-killing) substance that is linked to a monoclonal antibody.
Danish: Det aktive stof i Mylotarg, gemtuzumab ozogamicin, er et stof, der er giftigt for celler (cytotoksisk), og som er bundet til et monoklonalt antistof.
English: Complete remission is when the leukaemia cells can no longer be detected in the blood and are at very low levels in the bone marrow.
Danish: Fuldstændig bedring er, når der ikke længere kan påvises leukæmiceller i blodet, og når knoglemarven kun indeholder et meget
English: Hence, the CHMP recommended that Mylotarg be refused marketing authorisation.
Danish: CHMP anbefalede derfor at give afslag på ansøgningen om markedsføringstilladelse for Mylotarg.
English: The study was then extended to four years.
Danish: Studiet blev derefter forlænget til fire år.
English: All patients should be assessed at least once every two years.
Danish: Alle patienter bør vurderes mindst én gang hvert andet år.
English: Rebif received a marketing authorisation valid throughout the EU on 4 May 1998.
Danish: Rebif fik en markedsføringstilladelse med gyldighed i hele EU den 4. maj 1998.
English: Other information about Rebif
Danish: Andre oplysninger om Rebif
English: Further information on Rebif can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/rebif.
Danish: Yderligere information om Rebif findes på agenturets websted under: ema.europa.eu/medicines/human/EPAR/rebif.
English: As for all medicines, data on the use of Rebif are continuously monitored.
Danish: Som for alle lægemidler bliver data vedrørende brug af Rebif løbende overvåget.
English: What is Rebif and what is it used for?
Danish: Hvad er Rebif, og hvad anvendes det til?
English: The patients had experienced at least two relapses in the previous two years.
Danish: Patienterne havde haft mindst to tilbagefald i de foregående to år.
English: What measures are being taken to ensure the safe and effective use of Rebif?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Rebif?
English: A 22-microgram dose is recommended for patients who cannot tolerate the higher dose.
Danish: Det anbefales at give en dosis på 22 mikrogram til patienter, som ikke kan tåle den højere dosis.
English: Why is Rebif authorised in the EU?
Danish: Hvorfor er Rebif godkendt i EU?
English: An overview of Rebif and why it is authorised in the EU
Danish: En oversigt over Rebif, og hvorfor det er godkendt i EU
English: The European Medicines Agency decided that Rebif's benefits are greater than its risks and it can be authorised for use in the EU.
Danish: Det Europæiske Lægemiddelagentur konkluderede, at fordelene ved Rebif opvejer risiciene, og at det kan godkendes til anvendelse i EU.
English: Side effects reported with Rebif are carefully evaluated and any necessary action taken to protect patients.
Danish: De indberettede bivirkninger ved Rebif vurderes omhyggeligt, og der træffes de nødvendige forholdsregler for at beskytte patienterne.
English: When first starting treatment with Rebif, the dose should be slowly increased from a starting dose of 8.8 micrograms three times a week to avoid side effects.
Danish: Når behandlingen med Rebif indledes, bør dosen øges langsomt fra en startdosis på 8,8 mikrogram tre gange om ugen for at undgå bivirkninger.
English: The patients can inject Rebif themselves once they have been trained.
Danish: Patienterne kan godt selv indsprøjte Rebif, når de er blevet instrueret i det.
English: Some effect on progression of disability could be seen, but only in the patients who had relapses in the two years before the start of the study.
Danish: Der sås en vis virkning på forværringen af invaliditeten, men kun hos de patienter, der havde haft tilbagefald i de to år inden forsøgets start.
English: The recommended dose of Rebif is 44 micrograms given three times a week by injection under the skin.
Danish: Den anbefalede dosis af Rebif er 44 mikrogram givet tre gange om ugen ved injektion under huden.
English: What are the risks associated with Rebif?
Danish: Hvilke risici er der forbundet med Rebif?
English: The doctor may advise the patient to take a fever-reducing painkiller before each injection and for 24 hours after injection to reduce the influenza (flu)-like symptoms that may occur as a side effect of treatment.
Danish: Lægen kan råde patienten til at tage feberreducerende smertestillende medicin før hver injektion og i 24 timer efter injektionen for at reducere de influenzalignende symptomer, der kan optræde som bivirkning ved behandlingen.
English: The probability of developing MS over 24 months was 62.5% for patients given Rebif three times a week and 75.5% for patients given Rebif once a week compared with 85.8% for patients given placebo.
Danish: Sandsynligheden for forværring af multipel sklerose over en periode på 24 måneder var 62,5 % for de patienter, der fik Rebif tre gange om ugen, og 75,5 % for de patienter, der fik Rebif én gang om ugen, sammenlignet med 85,8 % for de patienter, der fik placebo.
English: For more information about using Rebif, see the package leaflet or contact your doctor or pharmacist.
Danish: Hvis du ønsker mere information om anvendelsen af Rebif, kan du læse indlægssedlen eller kontakte lægen eller apotekspersonalet.
English: Rebif (44 micrograms given once or three times a week) has also been compared with placebo in 515 patients who had experienced a single attack of demyelination.
Danish: Rebif (44 mikrogram givet én eller tre gange om ugen) blev også sammenlignet med placebo hos 515 patienter, som havde haft et enkelt attak af demyelinisering.
English: Rebif must not be used in patients who have severe depression or have thoughts of suicide.
Danish: Rebif må ikke anvendes til patienter med svær depression eller selvmordstanker.
English: Patients received either Rebif (22 or 44 micrograms) or placebo (a dummy treatment) for two years.
Danish: Patienterne fik enten Rebif (22 eller 44 mikrogram) eller placebo (en uvirksom behandling) i to år.
English: The most common side effects with Rebif (which may affect more than 1 in 10 people) are flu-like symptoms, neutropenia, lymphopenia and leucopenia (low white blood cell counts), thrombocytopenia (low blood platelet counts), anaemia (low red blood cell counts), headache, inflammation and other reactions at the injection site, and increases in transaminases (liver enzymes).
Danish: De hyppigste bivirkninger ved Rebif (som kan forekomme hos mere end 1 ud af 10 personer) er influenzalignende symptomer, neutropeni, lymfopeni og leukopeni (lavt antal hvide blodlegemer), trombocytopeni (lavt antal blodplader), anæmi (lavt antal røde blodlegemer), hovedpine, betændelse og andre reaktioner på injektionsstedet samt stigninger i leverenzymerne (transaminaser).
English: Rebif can also be used in patients who have had a single attack of demyelination accompanied by inflammation.
Danish: Rebif kan også anvendes til patienter, der har haft et enkelt attak af demyelinisering ledsaget af betændelse.
English: The active substance in Rebif is the protein interferon beta-1a, one of a group of interferons that can be naturally produced by the body to help it fight against viruses and other attacks.
Danish: Det aktive stof i Rebif er proteininterferonet beta-1a, der tilhører en gruppe interferoner, som kan dannes naturligt i kroppen for at hjælpe den med at bekæmpe virus og andre angreb.
English: For the full list of side effects and restrictions with Rebif, see the package leaflet.
Danish: Den fuldstændige liste over bivirkninger og begrænsninger ved Rebif fremgår af indlægssedlen.
English: Rebif contains the active substance interferon beta-1a.
Danish: Rebif indeholder det aktive stof interferon beta-1a.
English: How is Rebif used?
Danish: Hvordan anvendes Rebif?
English: The exact way that Rebif works in MS is not yet known but the active substance, interferon beta-1a, seems to calm down the immune system, and prevents relapses of MS.
Danish: Det vides endnu ikke med sikkerhed, hvordan Rebif virker ved multipel sklerose, men det aktive stof, interferon beta-1a, synes at berolige immunsystemet og forebygger tilbagefald af multipel sklerose.
English: Rebif was more effective than placebo in reducing the number of relapses in relapsing MS. Relapses were reduced by about 30% over two years for both Rebif 22 and 44 micrograms compared with placebo, and by 22% (Rebif 22 micrograms) and 29% (Rebif 44 micrograms) over four years.
Danish: Tilbagefaldene blev reduceret med ca. 30 % over to år for både 22 og 44 mikrogram Rebif sammenlignet med placebo, og med 22 % (22 mikrogram Rebif) og med 29 % (44 mikrogram Rebif) over fire år.
English: What benefits of Rebif have been shown in studies?
Danish: Hvilke fordele viser studierne, at der er ved Rebif?
English: Rebif can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of MS.
Danish: Rebif fås kun på recept, og behandlingen bør iværksættes af en læge med erfaring i behandling af multipel sklerose.
English: Rebif is available as a solution for injection in prefilled syringes, prefilled pens and cartridges for use in an electronic injection device.
Danish: Rebif fås som en injektionsvæske, opløsning, i fyldte sprøjter, fyldte penne og cylinderampuller til brug i en elektronisk injektionsanordning.
English: Rebif is a medicine used to treat patients with relapsing multiple sclerosis (MS).
Danish: Rebif er et lægemiddel til behandling af patienter med recidiverende multipel sklerose.
English: Rebif's effectiveness has not been shown in patients with secondary progressive MS (the type of MS that comes after relapsing MS) that is not relapsing.
Danish: Rebifs virkning er ikke påvist hos patienter med sekundær progressiv multipel sklerose (den type multipel sklerose, der kommer efter recidiverende multipel sklerose), som ikke giver tilbagefald.
English: Rebif has been studied in 560 patients with relapsing MS.
Danish: Rebif blev undersøgt hos 560 patienter med tilbagefald af multipel sklerose.
English: Relapsing MS is the type of MS where the patient has attacks (relapses) between periods with no symptoms.
Danish: Ved recidiverende multipel sklerose oplever patienten attakker (tilbagefald) mellem perioder uden symptomer.
English: How does Rebif work?
Danish: Hvordan virker Rebif?